Saturday 17 October 2026
Export ARGX’s income statement to Excel — free account
argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
819.14
27.13
−3.21%
Follow ARGX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
29.27 | 39.97 | 30.23 | 33.47 |
P/S ratio |
12.28 | 12.13 | 9.53 | 10.85 | |
P/FCF ratio |
0.00 | 87.59 | 77.00 | 41.94 | |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | |
P/B ratio |
7.43 | 7.04 | 6.19 | 6.87 | |
Price to Tangible BV |
7.70 | 7.31 | 6.43 | 7.09 | |
EV/Sales |
11.71 | 11.31 | 8.80 | 10.18 | |
EV/EBITDA |
54.72 | 45.61 | 31.96 | 33.86 | |
EV/Operating CF |
(162.51) | 57.23 | 49.81 | 33.57 | |
EV/FCF |
(96.14) | 81.66 | 71.08 | 39.34 | |
Quick Ratio |
— | 3.90 | — | 3.51 | |
Current Ratio |
— | 5.23 | — | 5.12 | |
Net Debt/EBITDA |
0.00 | (9.50) | 0.00 | (7.26) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
— | 0.00 | — | 0.00 | |
Asset Turnover |
0.00 | 0.64 | 0.00 | 0.72 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (3.97) | — | (0.47) | |
Interest Coverage |
348.63 | 337.57 | 394.00 | 494.00 | |
Research and Development Expense of Revenue |
30.89% | 27.78% | 33.74% | 31.52% | |
Selling, General and Administrative Expense of Revenue |
29.21% | 32.49% | 27.04% | 27.04% | |
Intangible Assets out of Total Assets |
0.00 | 0.03 | 0.00 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.10 | 0.11 | 0.12 | 0.11 | |
Graham Number |
0.00 | 237.82 | 0.00 | 290.25 | |
Earnings Yield |
3.42% | 2.50% | 3.31% | 2.99% | |
Free Cash Flow Yield |
(0.99%) | 1.14% | 1.30% | 2.38% | |
Revenue per Share |
18.76 | 21.58 | 21.16 | 24.75 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 56.95 | 0.00 | 57.52 | |
Shareholders Equity per Share |
0.00 | 119.47 | 0.00 | 135.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 119.47 | 0.00 | 135.08 | |
Free Cash Flow |
— | 573.51 | — | 643.00 | |
Working Capital |
— | 5,579.00 | — | 6,493.00 | |
Capital Expenditures |
— | (111.68) | — | (8.00) | |
Net Current Asset Value |
— | 5,539.00 | — | 6,453.00 | |
EV/EBIT |
54.72 | 45.61 | 31.96 | 33.86 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
57.35 | 48.91 | 34.62 | 36.09 | |
| Other line items | |||||
Average Receivables |
— | 1,078.14 | — | 1,298.28 | |
Average Payables |
— | 840.51 | — | 997.41 | |
Average Inventory |
— | 392.28 | — | 348.73 | |
Average Assets |
0.00 | 6,612.73 | 0.00 | 7,414.28 | |
Average Common Equity |
— | 5,710.25 | — | 6,339.62 |
Columns are period end dates